Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

February 1, 2010

Primary Completion Date

December 16, 2010

Study Completion Date

December 16, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec

Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted

DRUG

insulin glargine

Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted

Trial Locations (53)

104

Novo Nordisk Investigational Site, Taipei

220

Novo Nordisk Investigational Site, Banqiao District

500

Novo Nordisk Investigational Site, Changhua

600

Novo Nordisk Investigational Site, Chiayi City

807

Novo Nordisk Investigational Site, Kaoshiung

813

Novo Nordisk Investigational Site, Kaohsiung City

10330

Novo Nordisk Investigational Site, Bangkok

10380

Novo Nordisk Investigational Site, Goyang

10400

Novo Nordisk Investigational Site, Bangkok

10450

Novo Nordisk Investigational Site, Georgetown, Penang

10459

Novo Nordisk Investigational Site, George Town

10700

Novo Nordisk Investigational Site, Bangkoknoi, Bangkok

14647

Novo Nordisk Investigational Site, Bucheon-si

16150

Novo Nordisk Investigational Site, Kota Bharu, Kelantan

16247

Novo Nordisk Investigational Site, Suwon

16499

Novo Nordisk Investigational Site, Suwon

30000

Novo Nordisk Investigational Site, Nakhon Ratchasima

46150

Novo Nordisk Investigational Site, Kuala Selangor

50200

Novo Nordisk Investigational Site, Chiang Mai

50586

Novo Nordisk Investigational Site, Kuala Lumpur

56000

Novo Nordisk Investigational Site, Cheras

59100

Novo Nordisk Investigational Site, Kuala Lumpur

62250

Novo Nordisk Investigational Site, Putrajaya

90110

Novo Nordisk Investigational Site, Songkhla

Unknown

Novo Nordisk Investigational Site, Shatin, New Territories

Novo Nordisk Investigational Site, Taichung

103 0002

Novo Nordisk Investigational Site, Chuo-ku, Tokyo

247 0072

Novo Nordisk Investigational Site, Kamakura-shi, Kanagawa

212 0024

Novo Nordisk Investigational Site, Kawasaki-shi

880 0034

Novo Nordisk Investigational Site, Miyazaki

311 0113

Novo Nordisk Investigational Site, Naka-shi, Ibaraki

662 0971

Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo

355 0321

Novo Nordisk Investigational Site, Ogawa

144 0035

Novo Nordisk Investigational Site, Ota-ku, Tokyo

323 0022

Novo Nordisk Investigational Site, Oyama-shi, Tochigi

870 0039

Novo Nordisk Investigational Site, Ōita

060-0001

Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido

569 1096

Novo Nordisk Investigational Site, Takatsuki-shi, Osaka

614-735

Novo Nordisk Investigational Site, Busan

410-719

Novo Nordisk Investigational Site, Goyang

400-103

Novo Nordisk Investigational Site, Incheon

561-712

Novo Nordisk Investigational Site, Jeonju

110-746

Novo Nordisk Investigational Site, Seoul

120-752

Novo Nordisk Investigational Site, Seoul

130-701

Novo Nordisk Investigational Site, Seoul

133-792

Novo Nordisk Investigational Site, Seoul

135-239

Novo Nordisk Investigational Site, Seoul

135-720

Novo Nordisk Investigational Site, Seoul

139-827

Novo Nordisk Investigational Site, Seoul

150-950

Novo Nordisk Investigational Site, Seoul

158-710

Novo Nordisk Investigational Site, Seoul

220-701

Novo Nordisk Investigational Site, Wŏnju

626-770

Novo Nordisk Investigational Site, Yangsan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01059799 - Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter